2023 annual financial data
BridgeBio Oncology Therapeutics 2023 Operating margin
BridgeBio Oncology Therapeutics 2023 operating margin with verified reported va…
Direct answer
Operating margin was Not calculable.
Operating income was -64,771,000 USD and net income was -64,699,000 USD.
Operating cash flow was -52,079,000 USD.
Get free BridgeBio Oncology Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -64,771,000 USD
- Net income
- -64,699,000 USD
- Operating cash flow
- -52,079,000 USD
Explore related company data
View all 2023 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Net marginView Operating cash flow marginView all BridgeBio Oncology Therapeutics financial years